The use of osteoclast inhibitors in metastatic breast cancer

1. Cardoso F, Kataja V, Tjan-Heijnen V. Breast Cancer: Essentials for Clinicians. 2017; Lugano. Search in Google Scholar

2. Zhang H, Zhu W, Biskup E, Yang W, Yang Z, Wang H, Qiu X, Zhang C, Hu G, Hu G. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SRES) in breast cancer patients: A systematic review of the Real World Data. Journal of Bone Oncology. 2018. https://www.sciencedirect.com/science/article/pii/S2212137417301446.10.1016/j.jbo.2018.01.004583267629511626 Search in Google Scholar

3. Oster G, Lamerato L, Glass AG et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013; 21:3279-3286.10.1007/s00520-013-1887-323884473 Search in Google Scholar

4. Manfrida S, Masiello V, Cellini F, Adducci E, Polidori L, Longo S, Cannelli G, Balducci M, Rossi M, Valentini V. Improved Management (IM-MA study) in cancer-related pain: The value of a joint approach by an integrated team of radiotherapist and Anesthetist. Supportive Care in Cancer. 2018; 27(2),505-512. https://doi.org/10.1007/s00520-018-4335-6.10.1007/s00520-018-4335-629980908 Search in Google Scholar

5. Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 2011; 11(1). https://doi.org/10.1186/1471-2407-11-29.10.1186/1471-2407-11-29303792221261987 Search in Google Scholar

6. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-5139. doi: 10.1200/JCO.2010.29.7101.21060033 Open DOISearch in Google Scholar

7. Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. Oncology letters. 2014; 7(6):1997-2002. https://doi.org/10.3892/ol.2014.1982.10.3892/ol.2014.1982404972524932278 Search in Google Scholar

8. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur. J. Cancer. 2000; 36(4):476-482.10.1016/S0959-8049(99)00331-7 Search in Google Scholar

9. Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013; 119(4):832-838. https://doi.org/10.1002/cncr.27789.10.1002/cncr.2778922951813 Search in Google Scholar

10. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-1867. https://doi.org/10.1002/cncr.22991.10.1002/cncr.2299117763372 Search in Google Scholar

11. Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum Sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: A randomized, head-to-head clinical trial. The Journal of Clinical Endocrinology Metabolism. 2013; 98(8):3206-3212. https://doi.org/10.1210/jc.2013-1402.10.1210/jc.2013-140223788684 Search in Google Scholar

12. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AHG, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone-related complications and quality of life in Advanced breast cancer: Results from a randomized phase III trial of denosumab versus Zoledronic acid. Clinical Cancer Research. 2012; 18(17):4841-4849. https://doi.org/10.1158/1078-0432.ccr-11-3310.10.1158/1078-0432.CCR-11-331022893628 Search in Google Scholar

13. Zhang C, Zhang F, Liang G et al. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years. BMC Musculoskelet Disord. 2018; 19,424. https://doi.org/10.1186/s12891-018-2338-6.10.1186/s12891-018-2338-6626705730497434 Search in Google Scholar

14. Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Increased risk of multiple spontaneous vertebral fractures at denosumab discontinuation must be taken into account. Journal of Clinical Oncology. 2020; 38(14):1641-1642. https://doi.org/10.1200/jco.19.02678.10.1200/JCO.19.0267832208054 Search in Google Scholar

15. Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne. 2018; 190(16):E485-E486. https://doi.org/10.1503/cmaj.180115.10.1503/cmaj.180115591524429685907 Search in Google Scholar

16. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res. Treat. 2012; 131(1):231-238.10.1007/s10549-011-1721-x Search in Google Scholar

17. Robson P. Metastatic spinal cord compression: a rare but important complication of cancer. Clinical medicine (London, England). 2014; 14(5):542-545. https://doi.org/10.7861/clinmedicine.14-5-542.10.7861/clinmedicine.14-5-542495196825301920 Search in Google Scholar

18. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ (Clinical research ed.). 2003; 327(7413):469. https://doi.org/10.1136/bmj.327.7413.469.10.1136/bmj.327.7413.46918842712946966 Search in Google Scholar

19. Al Farii H, Frazer A, Farahdel L, Alfayez S, Weber M. Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials. Global spine journal. 2020; 10(6):784-789. https://doi.org/10.1177/2192568219884069.10.1177/2192568219884069738378832707021 Search in Google Scholar

20. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future oncology (London, England). 2015; 11(21):2865-2871. https://doi.org/10.2217/fon.15.232.10.2217/fon.15.232497685826403973 Search in Google Scholar

21. Diel IJ, Body J-J, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer. 2015; 51(11):1467-1475. https://doi.org/10.1016/j.ejca.2015.04.017.10.1016/j.ejca.2015.04.01725976743 Search in Google Scholar

22. Morgan KP, Sun Y, Deal A, Weiss J, Cipriani A. Denosumab for first-line treatment of hypercalcemia associated with malignancy: Retrospective analysis. The Journal of Hematology Oncology Pharmacy. 2021. https://jhoponline.com/jhop-issue-archive/2021-issues/june-2021-vol-11-no-3/18933-denosumab-for-first-line-treatment-of-hypercalcemia-associated-with-malignancy-retrospective-analysis. Search in Google Scholar

23. Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: A systematic review. Bone Reports. 2021; 15,101148. https://doi.org/10.1016/j.bonr.10.1016/j.bonr.2021.101148 Search in Google Scholar

24. Pielkenrood BJ, Gal R, Kasperts N, Verhoeff JJC, Bartels MMTJ, Seravalli E, van der Linden YM, Monninkhof EM, Verlaan J-J, van der Velden JM, Verkooijen HM. Quality of life after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases. International Journal of Radiation Oncology*Biology*Physics. 2022; 112(5):1203-1215. https://doi.org/10.1016/j.ijrobp.2021.12.163.10.1016/j.ijrobp.2021.12.16335017007 Search in Google Scholar

25. Aleissa S, Konbaz F, Alsebayel F, Eissa A, Alogayyel N, Alhandi A, Almajed M, Bourghli A, Alhelal F, Abaalkhail M. The morbidity and mortality rates following surgery in metastatic spine disease patients. Journal of Spine Practice (JSP). 2022; 54-61. https://doi.org/10.18502/jsp.v1i2.9902.10.18502/jsp.v1i2.9902 Search in Google Scholar

26. Green DE, Rubin CT. Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone. 2014; 63:87-94. https://doi.org/10.1016/j.bone.2014.02.018.10.1016/j.bone.2014.02.018400592824607941 Search in Google Scholar

27. Wang Z, Qiao D, Lu Y et al. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. The Oncologist. 2015; 20(4):440-449. doi: 10.1634/theoncologist.2014-0328.439176425732263 Open DOISearch in Google Scholar

28. Jackson C, Freeman ALJ, Szlamka Z, Spiegelhalter DJ. The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis. PLOS ONE. 2021; 16(2):e0246441. https://doi.org/10.1371/journal.pone.0246441.10.1371/journal.pone.0246441786440033544765 Search in Google Scholar

29. Wright E, Schofield PT, Molokhia M. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis. BMJ Open. 2015; 5:e007133.10.1136/bmjopen-2014-007133468000026644118 Search in Google Scholar

30. Zoledronic acid [package insert]. Iceland: Actavis Group PTC ehf; 2012. https://www.ema.europa.eu/en/documents/product-information/zoledronic-acid-actavis-epar-product-information_en.pdf. Search in Google Scholar

31. Bone HG, Wagman RB, Brandi ML et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5:513.10.1016/S2213-8587(17)30138-928546097 Search in Google Scholar

32. Leder BZ. An Essential Warning. J Bone Miner Res. 2018; 33:188.10.1002/jbmr.335929232486 Search in Google Scholar

33. Denosumab [package insert]. The Netherlands: Amgen Europe B.V.; 2010. https://www.ema.europa.eu/en/documents/product-information/prolia-epar-product-information_en.pdf. Search in Google Scholar